Incidence of urinary retention during treatment with single tablet combinations of solifenacin plus tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies

Marcus J. Drake*, Matthias Oelke, Robert Snijder, Monique Klaver, Klaudia Traudtner, Karin van Charldorp, Dominique Bongaerts, Philip Van Kerrebroeck

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction The emergence of urinary retention (UR), specifically acute urinary retention (AUR), has been a concern when treating men with lower urinary tract symptoms (LUTS) with antimuscarinic drugs.

Materials and methods

In NEPTUNE (12-week, double-blind), men (>= 45 years) with LUTS were randomized to receive tamsulosin oral-controlled absorption system (TOCAS) 0.4 mg, fixed-dose combination (FDC) of solifenacin (Soli) 6 mg + TOCAS 0.4 mg, FDC Soli 9 mg + TOCAS 0.4 mg, or placebo. In NEPTUNE II (40-week, open-label extension of NEPTUNE), continuing patients received 4 -week FDC Soli 6 mg + TOCAS, then FDC Soli 6 mg or 9 mg + TOCAS for the remainder of the study, switchable every 3 months.

Results

Across both studies, 1208 men received >= 1 dose of FDC Soli 6 mg or 9 mg + TOCAS for up to 52 weeks; 1199 men completed NEPTUNE and 1066 received >= 1 dose in NEPTUNE II. In total, 13 men (1.1%; 95% CI, 0.6%-1.8%) reported a UR event while receiving FDC, eight of which were AUR (0.7%; 95% CI, 0.3%-1.3%, incidence 7/1000 man-years). Six men reported UR events while taking Soli 6 mg + TOCAS (three AUR), and seven men reported a UR event while taking Soli 9 mg + TOCAS (five AUR). One man developed AUR while taking TOCAS alone and four reported UR (three AUR) during placebo run-in. Most AUR/UR events occurred within 4 months of treatment initiation.

Conclusions

FDC Soli and TOCAS was associated with a low rate of UR and AUR in men with LUTS.

Original languageEnglish
Article number0170726
Number of pages11
JournalPLOS ONE
Volume12
Issue number2
DOIs
Publication statusPublished - 6 Feb 2017

Keywords

  • BLADDER OUTLET OBSTRUCTION
  • TRACT SYMPTOMS
  • OVERACTIVE BLADDER
  • GUIDELINES
  • EFFICACY
  • THERAPY
  • SAFETY
  • TRIAL

Cite this